When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care

This episode, titled 'When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care,' features panelists discussing the following critical questions:

1. Beyond the clinical definition, how do you define a "treatment failure" for a patient with a debilitating mental disorder, such as MDD, bipolar depression, or schizophrenia?
2. How do you approach next treatment steps for patients experiencing treatment failure?

The panelists examined how treatment failure in serious mental illness extends beyond clinical metrics, encompassing a patient's continued inability to function in daily life and regain their sense of self, and that distinguishing between no response and partial response is critical, as it determines whether a clinician should switch therapies entirely or pursue augmentation strategies to build on existing benefit. The discussion highlighted that with each successive treatment failure, the probability of achieving response diminishes, making it essential to sustain patient engagement and morale by identifying even incremental improvements in target symptoms such as sleep, mood stability, and quality of life. The panelists also explored the evidence base for treatments in multi-treatment-resistant populations, noting that while most psychiatric medications carry small to medium effect sizes, a select few may offer meaningfully larger effects that should be considered earlier in the treatment algorithm rather than as last resorts.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures,' panelists will continue their discussion on major depressive disorder, bipolar depression, and schizophrenia and highlight how clinicians weigh branded versus generic options for treatment-resistant patients, and the degree to which system-level barriers such as prior authorization and step-therapy requirements influence clinical decision-making versus the pursuit of the clinical ideal.